Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

FORMA, TD2 leverage synergistic capabilities to jointly develop transformative cancer therapies

FORMA Therapeutics and TGen Drug Development (TD2) today announced an agreement to jointly develop transformative cancer therapies, leveraging the synergistic capabilities of both organizations.

19 Jun 2012

Zealand Pharma, Protagonist partner to develop novel disulfide-rich peptides

Zealand Pharma A/S, a Danish biotechnology company dedicated to the discovery and development of novel peptide drugs, has signed a collaboration agreement with Protagonist Therapeutics, Inc., a privately-owned US incorporated biotechnology company.

18 Jun 2012

Bristol-Myers Squibb, Scripps Research enter five-year collaboration

The Scripps Research Institute today announced it has entered into a five-year collaboration with Bristol-Myers Squibb Company focused on applying novel chemistry to drug discovery and synthesis.

16 Jun 2012

iPS Academia Japan, Life Technologies partner for induced pluripotent stem cell patent portfolio

Life Technologies Corporation today announced that it has deepened its commitment to stem cell research and its customers by signing a non-exclusive agreement with iPS Academia Japan for its induced pluripotent stem (iPS) cell patent portfolio.

16 Jun 2012

Third Rock Ventures announces formation of Global Blood Therapeutics

Third Rock Ventures, LLC today announced the formation of Global Blood Therapeutics, Inc. and its $40.7 million Series A financing of the company.

15 Jun 2012

Innovimmune receives $600,000 NIH grant to develop MIF inhibitors for RA

Specialty drug discovery company, Innovimmune Biotherapeutics, Inc. has been awarded a $600,000 Advanced Technology Small Business Innovation Research Grant from the National Institutes of Health (NIH).

14 Jun 2012

US Oncology Research, MMRF partner to participate in CoMMpass study

The Multiple Myeloma Research Foundation (MMRF) today announced an alliance with US Oncology Research to participate in the landmark CoMMpass (Relating Clinical Outcomes in MM to Personal Assessment of Genetic Profile) study sponsored by the MMRF.

14 Jun 2012

Human-derived stem cells can spontaneously form optic cups and retina

Human-derived stem cells can spontaneously form the tissue that develops into the part of the eye that allows us to see, according to a study published by Cell Press in the 5th anniversary issue of the journal Cell Stem Cell.

14 Jun 2012

DNDi, Astellas partner on new drug discovery research for treatment of NTDs

Astellas Pharma Inc. and the Drugs for Neglected Diseases initiative (DNDi) announced an agreement today to collaborate on drug discovery research for leishmaniasis, Chagas disease, and sleeping sickness - three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.

12 Jun 2012

CRT, BioInvent partner to identify new therapeutic antibodies in oncology

BioInvent International AB and Cancer Research Technology Ltd (CRT), the commercial arm of Cancer Research UK, announced today that they have entered a collaboration with Queen Mary, University of London, to identify new therapeutic antibodies in oncology.

12 Jun 2012

Fate Therapeutics, BD Biosciences introduce first collaborative iPSC-related product

Fate Therapeutics, Inc. in collaboration with BD Biosciences, a segment of BD (Becton, Dickinson and Company), today announced the introduction of the first induced pluripotent stem cell (iPSC)-related product resulting from the collaboration between the two companies.

From BD (Becton, Dickinson and Company) 11 Jun 2012

Cambridge facility to become worldwide hub for SAFC's chiral service

Sigma-Aldrich Corporation today announced that its custom manufacturing and services business unit, SAFC, will consolidate its global chiral chromatography screening and small scale purification operations and locate them at its Pharmorphix Solid State Research Laboratories in Cambridge, UK, to support its new integrated chiral chemistry offer.

11 Jun 2012

ADAM28 inhibits VWF-mediated cancer cell apoptosis and enhances lung metastases

ADAM28, a metalloproteinase belonging to the ADAM gene family, cleaves the von Willebrand factor (VWF) and inhibits VWF-mediated cancer cell apoptosis, thereby enhancing lung metastases, so inhibiting its expression gives a substantial reduction in lung metastases, according to a study published June 8 in the Journal of The National Cancer Institute.

11 Jun 2012

Scientists create cancer model built in the fruit fly Drosophila

Researchers from Mount Sinai School of Medicine developed a cancer model built in the fruit fly Drosophila, then used it to create a whole new approach to the discovery of cancer treatments. The result is an investigational compound AD80 that precisely targets multiple cancer genes.

8 Jun 2012

CDI introduces MyCell Services

Cellular Dynamics International, Inc. (CDI), the world's largest commercial producer of human induced pluripotent stem (iPS) cell lines and tissue cells, today announced the launch of its MyCell Services.

7 Jun 2012

Investigational diabetes drug appears to improve insulin sensitivity without side effects

Drugs for type 2 diabetes can contribute to weight gain, bone fractures and cardiovascular problems, but in mice, an investigational drug appears to improve insulin sensitivity without those troublesome side effects, researchers at Washington University School of Medicine in St. Louis have shown.

5 Jun 2012